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Background: We hypothesized that lung cancer patient’s circulating microparticles (Lc-MPs) could promote
angiogenesis, blood flow in ischemic zone and ischemic recovery in rat critical limb ischemia (CLI).
Methods: To investigate the impact of MP therapy on reversing the setting of CLI, adult-male Sprague–Dawley rats
(n=50) equally randomized into sham control (SC) (group 1), SC-Lc-MPs (1.0 x 107 particles) (group 2), CLI (group 3),
CLI-Hs-MPs (MPs from healthy-subject) (group 4), and CLI-Lc-MPs (group 5) were sacrificed by post-CLI day-14.
Results: In vitro study showed that Lc-MPs enhanced VEGFR2 expression, angiogenesis, nitric-oxide production, and
endothelial cell proliferation (all p<0.005). By days 7 and 14, Laser Doppler showed significantly higher ischemic/normal
blood-flow ratio in groups 1 and 2 compared with group 3, and was significantly higher in group 4 and further
elevated in group 5 (p<0.0001). Numbers of small vessels and endothelial markers (CD31+ and vWF+ cells) and protein
expressions (eNOS, CD31) exhibited a pattern identical to Lasre Doppler among the five groups (all p<0.001).
Pro-angiogenic factors (VEGF, CXCR4, SDF-1α, HGF) at cellular and protein levels showed a significant step-wise
increase from groups 1 and 2 to groups 3, 4, and 5 (all p<0.001). Protein expressions of fibrotic (Smad3, TGF-β) and
apoptotic (mitochondrial Bax, cleaved caspase 3, and PARP) biomarkers displayed an opposite pattern compared to that
of Laser Doppler, whereas the protein expressions of anti-fibrotic (Smad1/5, BMP-2) and anti-apoptotic (Bcl-2) biomarkers
showed an identical pattern compared with that of Laser Doppler among groups 1 to 3, and 5 (all p<0.001).
Conclusion: Administration of Lc-MPs augmented angiogenesis and restored blood flow in a rat of CLI.
Keywords: Lung cancer, Circulating microparticles, Critical limb ischemia, Angiogenesis, Blood-flow restorationIntroduction
Lung cancer (LC) is the most common cause of cancer-
related mortality worldwide [1,2] with non-small-cell lung
cancer (NSCLC) accounting for approximately 85% of all
cases. Approximately 70% of NSCLC patients who present
with locally advanced or metastatic disease have a poor* Correspondence: lawrence.c.k.sun@gmail.com; han.gung@msa.hinet.net
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unless otherwise stated.prognosis, with an expected 5-year survival rate of <5%
[3,4]. Despite various combinations of surgery, radiother-
apy and chemotherapy [2,5,6], overall survival rates re-
main poor [7-10]. A better understanding of what is
the key factors for locally advanced and metastatic dis-
ease states may be very important for improving LC
therapeutic outcomes.
Microparticles (MPs) are identified as “small plasma
membrane fragments” of cells shed into the circulation
by activated and/or apoptotic cells in response to changes
such as physiological stimulations (thrombin, endotoxin
or shear stress), stress, cellular apoptosis (growth factor
deprivation or apoptotic inducers), and/or neoplastichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sheu et al. Journal of Translational Medicine  (2015) 13:59 Page 2 of 15transformation [11-16]. Interestingly, MPs appear to
have differential roles in angiogenesis depending on
their origin [14-20]. Of note, MPs exhibit pro-
angiogenic activity, in that they promote formation of
capillary-like structures and pro-angiogenic factor pro-
duction [14,16,17,19,20]. Accumulating published evi-
dence indicates that numbers of circulating MPs are
increased in various type of cancer, including LC
[21-23]. We have also recently displayed that circulating
levels of MPs are significantly increased in LC patients,
and circulating levels of endothelial-derived apoptotic
MPs are significantly associated with different LC cell
types [24]. These studies raise the possibility that circu-
lating MPs are not only biomarkers but may also dir-
ectly participate in angiogenesis for promoting nutrient
delivery to LC cells, local invasion and metastasis. How-
ever, these potentially important propositions remain
untested in the literature. To extend our recent work
[24], the aims of this study, which included both in vitro
and in vivo studies, were to address: (1) whether circulat-
ing MPs derived from LC patients promoted angiogenesis,
differentiation, nitric oxide (NO) production and vascular
endothelial growth factor receptor (VEGFR) expres-
sion in culturing human umbilical vein endothelial
cells (HUVECs); and (2) whether administration of
MPs rescued rat critical limb ischemia (CLI) mainly
through angiogenesis and enhanced blood flow in is-
chemic regions.
Materials and methods
Ethics
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at Kao-
hsiung Chang Gung Memorial Hospital and performed
in accordance with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85–23, National
Academy Press, Washington, DC, USA, revised 1996).
Rationale for the source and dosage of MPs
Because of the results of our recent study [24] that dem-
onstrated strong correlation between the circulating
level of MPs and poor prognostic outcome of patients at
advanced stages of NSCLC (i.e., stage IIIb or staged IV
of NSCLC upon presentation), MPs were obtained from
these patients in the present study.
First of all, the safety and efficacy of different regimens
of MP administration were compared in the current
study. Second, the amount of MPs that could be ob-
tained from one patient was determined based on our
knowledge that usually about 1.0 × 107 MPs could be
harvested from10 mL of patient’s blood. Therefore, our
pilot study used four animals for verification of dosage
of MPs for the current study, including one with CLI
only and another three animals receiving 1.0 × 106, 5.0 ×106 and 1.0 × 107 MPs, respectively. By day 14, the results
of Laser Doppler showed that the blood flow to the ische-
mic limb was highest in animals treated with the high-dose
regimen (i.e., 1.0 x 107 MPs) without notable complication
or tumorigenesis. Therefore, the high-dose regimen
(1.0 × 107 MPs) was used in subsequent experiments.
Animal model of critical limb ischemia, animal grouping,
and treatments
The procedure and protocol were based on our previous
reports [25,26]. In brief, male Sprague–Dawley (SD) rats
in CLI groups were anesthetized by inhalation of 2.0%
isoflurane. The rats were placed in a supine position on
a warming pad at 37°C with the left hind limbs shaved.
Under sterile conditions, the left femoral artery, small
arterioles, circumferential femoral artery and veins were
exposed and ligated over their proximal and distal por-
tions before removal. To avoid the presence of collateral
circulation, the branches were removed together. For
Laser Doppler study, 10 rats in each group were utilized
and 8 rats in each group were used for cellular-molecular
assessment. For animals that served as normal controls
with and without receiving MPs, the arteries were only
isolated without ligation.
The SD rats (n=40) were equally divided into four
groups: group 1 [sham control (SC) + 1.0 ml phosphate
buffered saline (BPS) (0.5 ml from penile vein injection
and 0.5 ml via intra-muscular injection], group 2 [SC +
lung cancer-derived (Lc)-MPs (1.0 × 107 particles) in
1.0 cc BPS given as SC group)], group 3 (CLI only),
group 5 (CLI + Lc-MPs, 5.0 × 106 particles in 0.5 ml
BPS via penile vein injection and 5.0 × 106 particles in
0.5 ml BPS by intra-muscular injection into ischemic
zone) just after CLI induction. The rationale for adminis-
tration of MPs from both intravenous and intra-muscular
injection were to consider that combined circulatory and
localized therapy with MPs in a situation of CLI would be
offer a great enhancement of angiogenesis effect.
In the present study, another 10 animals (group 4) serves
as positive controls that received MPs from healthy sub-
jects (Hs) (i.e., Hs-MPs) after the CLI procedure to verify
the potential capacity of enhancing angiogenesis of Hs-
MPs in ischemic limbs. Laser Doppler, immunohistochem-
ical (IHC) staining, immunofluorescent (IF) and Western
blot studies were used for measuring blood flow, identifi-
cation of small blood vessel, and quantification of cellular
elements of angiogenesis [i.e., CD31+, CXCR4+, stromal
cell-derived factor (SDF)-1α+, von Willebrand factor
(vWF)+ and VEGF+ cells], respectively. All animals were
sacrificed on day 14 after the last Laser Doppler study.
Blood samples for determining plasma levels of microparticles
Blood samples (10 mL) were obtained at 9:00 am from
study subjects for individual analysis according to the
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[24]. In brief, peripheral blood was collected in acid cit-
rate dextrose (ACD) vacutainer tubes. To prepare
platelet-rich plasma, the peripheral blood (1.5 mL) was
centrifuged at 2500 × g at 4°C for 15 min without accel-
eration or break. The 250 μL plasma samples were
thawed and centrifuged for 10 min at 19,800 × g at 4°C,
and then collected for investigation of MPs smaller than
1.0 μm. Size calibration was conducted with 1.0 μm
beads (Invitrogen, Carlsbad, CA). All buffers were
sterile-filtered with a 0.2 μm filter.
In the present study, the pellet and non-purification of
the MPs were utilized. Additionally, because a large
amount of MPs should be utilized for one animal, thus
MPs were obtained from a pool of patients with the
same pathology for one individual study.
Measurement of blood flow with laser doppler (Figure 1)
The procedure and protocol were based on our previ-
ous reports [25,26]. In brief, rats were anesthetized by
inhalation of isoflurane (2.0%) prior to CLI induction
and at days 2, 7, 14 after CLI induction prior to sacrifice.
The rats were placed supine on a warming pad (37°C)
and blood flow was detected in both inguinal areas by a
Laser Doppler scanner (moorLDLS, Moor, Co. UK). The
ratio of flow in the left (ischemic) leg and right (normal)
leg was computed. By day 14, the rats were sacrificed
and the quadriceps muscle was collected for individual
study. Additionally, the lungs were collected to deter-
mine whether tumorigenesis was present or absent.
Cell culture
Commercialized human umbilical vein endothelial cells
(HUVECs) (BCRC) were utilized for the current study.
Cells were first grown at 37°C in a 100 mm culture dish
(Falcon) in M199 (Gibco) medium with endothelial cell
growth supplement, heparin, and 20% fetal bovine serum
(FBS) (Gibco). Cells of the third to fifth generation were
used in the current study (Additional file 1).
Method for determining Rat aortic-ring angiogenesis
Aortic-ring angiogenesis was conducted assay in twenty
four-well tissue culture plates were embed with 150 μL
of 1 mg/ml type I collagen (BD Biosciences, NJ) and
allowed to gel for 60 minutes at 37°C and 5% CO2. The
rat thoracic aorta was excised from 5- to 8-week-old
Sprague Dawley rat, then remove all extraneous tissue
and branching vessels with forceps and a scalpel. The
aorta was cut into 1 mm of cross-section, placed on
collagen-coated wells then filled with 500 μL of serum
free MCDB131 medium. These rings were incubated for
about 24 hours at 37°C and 5% CO2. After 24 hours,
aorta rings were treated or non-treatment with micro-
particles (6.0 x 105 MPs) for 12 days and photographedat first day and 12 days with 12.5x magnification. The
number and length of sprouting vessels were quantified
by OLYMPUS DP72 software. Experiments were re-
peated two times.
Western blot analyses
The procedure and protocol were based on our previous
reports [25,26]. Equal amounts (50 μg) of protein ex-
tracts were loaded and separated by SDS-PAGE using
acrylamide gradients. After electrophoresis, the sepa-
rated proteins were transferred electrophoretically to a
polyvinylidene difluoride (PVDF) membrane (Amersham
Biosciences). Nonspecific sites were blocked by incuba-
tion of the membrane in blocking buffer [5% nonfat dry
milk in T-TBS (TBS containing 0.05% Tween 20)] over-
night. The membranes were incubated with the indi-
cated primary antibodies [cytochrome c (Cyt c) (1: 2000,
BD, mouse monoclonal), Bax (1: 1000, Abcam, rabbit
polyclonal), caspase 3 (1:1000, Cell Signaling, rabbit
monoclonal), poly(ADP-ribose) polymerase (PARP)
(1:1000, Cell Signaling, rabbit polyclonal), Bcl-2 (1:200,
Abcam, rabbit polyclonal), endothelial nitric oxide syn-
thase (eNOS) (1: 1000, Abcam, rabbit polyclonal), VEGF
(1:1000, Abcam, mouse monoclonal), SDF-1α (1:1000,
Cell Signaling, rabbit polyclonal), CXCR4 (1:1000, Abcam,
rabbit polyclonal), CD31 (1:3000, Abcam, mouse mono-
clonal), angiopoietin (1:1000, Millipore, rabbit polyclonal)
hepatocyte growth factor (HGF) (1:1000, Abcam, Rabbit
polyclonal), b-FGF (1:1000, Abcam, rabbit polyclonal),
transforming growth factor (TGF)-β ( 1:500, Abcam,
rabbit polyclonal), Smad3 (1:1000, Cell Signaling, rabbit
polyclonal), bone morphogenetic protein (BMP)-2 (1:500,
Abcam, rabbit polyclonal), Smad1/5 (1:1000, Cell Signal-
ing, rabbit polyclonal), Actin (1:10000, Chemicon, mouse
monoclonal)] for 1 hour at room temperature. Horseradish
peroxidase-conjugated anti-rabbit or mouse IgG (1: 2000,
Cell Signaling) was used as a secondary antibody for one
hour at room temperature. The washing procedure was
repeated eight times within one hour, and immunoreactive
bands were visualized by enhanced chemiluminescence
(ECL; Amersham Biosciences) and exposure to Biomax L
film (Kodak). For purposes of quantification, ECL signals
were digitized using Labwork software (UVP).
Oxidative stress reaction in lower limb muscles
The Oxyblot Oxidized Protein Detection Kit was pur-
chased from Chemicon (S7150). DNPH derivatization
was carried out on 6 μg of protein for 15 minutes ac-
cording to manufacturer’s instructions. One-dimensional
electrophoresis was carried out on 12% SDS/polyacryl-
amide gel after DNPH derivatization. Proteins were
transferred to nitrocellulose membranes which were
then incubated in the primary antibody solution (anti-
DNP 1: 150) for 2 h, followed by incubation with
Figure 1 (See legend on next page.)
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Figure 1 Upper Panel) Matrigel Assay for angiogenesis with and without Patient’s Lung cancer-derived microparticles (Lc-MPs)
treatment (n = 6). A to C) After 5-hour cell culture [1.0 × 104 human umbilical vein endothelial cells (HUVECs)], Matrigel-assay angiogenesis was
observed by microscopic findings (100×) in without (A) and with Lc-MPs treatment [3.0 × 105 (B) and 6.0 × 105 (C) MPs, respectively]. D) Analytical
results of number of tubules (white arrows), * vs. other groups with different symbols (*, †, ‡), p < 0.001. E) Analytical results of total tubular length, * vs.
other groups with different symbols (*, †, ‡), p < 0.001. F) Analytical results of cluster formation (black arrows), * vs. other groups with different symbols
(*, †, ‡), p < 0.001. G) Analytical results of network formation (blue dot line), * vs. other groups with different symbols (*, †, ‡), p < 0.001. All statistical
analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Lower Panel) Aortic-ring (AR) angiogenesis
and nitric oxide (NO) production after lung-cancer microparticles (Lc-MPs) treatment (n = 6). H & I) By day-5 cell culturing, the angiogenesis did not
differ between with and without Lc-MPs treatment. J & K) By day-12 cell culturing, the AR angiogenesis was significantly enhanced in with (K) than in
without (J) Lc-MP treatment. N) Mean sprouting length, p < 0.0001, * vs. control group; O) Number of sprouts around aortic ring, p < 0.0001, *
vs. control group. L & M) Immunofluorescent microscopic finding of NO production by 6-hour after cell culture; P) The statistically analytic
results of fluorescent intensity of NO expression, p < 0.0001, * vs. control group.
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temperature. The washing procedure was repeated eight
times within 40 minutes. Immunoreactive bands were visu-
alized by enhanced chemiluminescence (ECL; Amersham
Biosciences) which was then exposed to Biomax L film
(Kodak). For quantification, ECL signals were digitized
using Labwork software (UVP). For oxyblot protein ana-
lysis, a standard control was loaded on each gel.
Immunofluorescent (IF) measurement
The procedure and protocol were described in our previ-
ous studies [25,26]. For IF staining, cryo-sections were
fixed with cold acetone for 3 minutes and then incubated
with primary antibody specifically against CD31 (1:200,
Serotec), vWF (1:100, Millipore), VEGF (1:100, Abcam),
CXCR4 (1:100, Santa Cruz), SDF-1α (1:200, Santa Cruz) at
4°C overnight. After being washed with PBS, muscle sec-
tions were incubated with Alexa Fluor 594-conjugated
goat anti-mouse IgG secondary antibodies for 30 minutes
at room temperature, followed by counter-staining with
DAPI. Fluorescent signals were observed with fluorescent-
equipped microscope (IX-41, Olympus).
Quantification of vessel density in limb ischemic area
The procedure and protocol were according to our pre-
vious reports [25,26]. Briefly, immunohistochemical
(IHC) staining of blood vessels was performed with α-
SMA (1:400) as primary antibody at room temperature
for 1 h, followed by washing with PBS thrice. Ten mi-
nutes after the addition of anti-mouse-HRP conjugated
secondary antibody, the tissue sections were washed
with PBS thrice. Then 3,3’ diaminobenzidine (DAB) (0.7
gm/tablet) (Sigma) was added, followed by washing with
PBS thrice after one minute. Finally, hematoxylin was
added as a counter-stain for nuclei, followed by washing
twice with PBS after one minute. Three sections of
quadriceps were analyzed in each rat. For quantification,
three randomly selected HPFs (200×) were analyzed in
each section. The mean number per HPF for each ani-
mal was then determined by summation of all numbers
divided by 9.Statistical analyses
Quantitative data are expressed as mean ± SD. Statistical
analysis was performed by ANOVA followed by Bonferroni
multiple-comparison post hoc test. All analyses were con-
ducted using SAS statistical software for Windows version
8.2 (SAS institute, Cary, NC). A probability value <0.05
was considered statistically significant.
Results
Microparticles promoted angiogenesis, NO production,
cell proliferation and VEGFR2 protein expression of
HUVECs (Figures 1 and 2)
Figure 1 (Upper Panel) (A to G) shows the effect of
Lc-MPs on angiogenesis at 5-hour HUVEC culture. As
compared with control group, the cluster, tubular, and
network formations on Matrigel assay were significantly
increased after the two regimens of Lc-MP treatment
(3.0 ×105 and 6.0 × 105) at 5-hour culturing interval. In-
triguingly, these parameters were significantly increased
in high-dose MP than that of low-dose MP treatment in
this culturing time interval.
Figure 1 (Lower Panel H to P) shows the impact of Lc-
MPs on angiogenesis of aortic ring. As expected, the
angiogenesis of aortic ring was significantly increased
with Lc-MP treatment compared with that without.
Additionally, the impact of Lc-MP treatment on NO
production in HUVECs was assayed in the present
study. As expected, NO production was significantly en-
hanced in HUVECs after Lc-MP treatment compared
with the non-treatment group.
Figure 2 (A to C) showed the effect of MP treatment
on BrdU uptake by HUVECs, an indicator of cell prolif-
eration. Consistent with the findings of NO production,
BrdU uptake by HUVECs was also augmented by Lc-MP
treatment, signifying an enhanced cellular proliferation
after Lc-MP treatment.
As compared with control group, the Lc-MP treat-
ment did not affect the protein expression of b-FGF in
HUVECs at the three time intervals (i.e., at 6, 12 and
24 h) (Figure 2-D to F). This finding suggests that the MP-
induced angiogenesis might not be through the b-FGF
Figure 2 HUVEC proliferation and protein expressions of pro-angiogenesis factors after lung-cancer microparticles (Lc-MPs) treatment
(n = 6). A & B) Immunohistochemical stain of BrdU uptake by HUVECs (gray color). C) The statistically analytic results of BrdU+cells, p < 0.0001,
* vs. control group. D, E & F) As compared with control group, the protein expression of basic-fibroblast growth factor (b-FGF) was not enhanced
by Lc-MP treatment at the three time intervals (6, 12 and 24 h) of HUVEC culture. However, as compared with that of control group, the protein
expression of b-FGF were significantly increased in HUVECs at time intervals of 12 and 24 h after vascular endothelial cell growth factor (VEGF)
(50 ng/mL) treatment. * vs. other groups with different symbols, p < 0.001. G, H & I) As compared with control group, the protein expression of
VEGFR2 in HUVECs were significantly augmented at 6 h and 12 h intervals and maintained at 24 h following Lc-MP treatment. * vs. other groups
with different symbols, p < 0.001. Additionally, this protein expression in HUVECs showed an identical pattern of b-FGF at time intervals of 12 and
24 h after VEGF (50 ng/mL) treatment. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test. Symbols (*, †, ‡, §, ¶) indicate significance (at 0.05 level).
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pression of this angiogenesis factor in HUVECs was sig-
nificantly enhanced by VEGF treatment at 12 h and 24 h
intervals.
The protein expression of VEGFR2 in HUVECs were
significantly increased at 6 h and 12 h intervals and main-
tained at 24 h following Lc-MP treatment (Figure 2-G to
I). These findings imply that VEGFR2 might be one of the
crucial signaling pathways (i.e., interaction between ligand
and receptor) for MPs to promote the capacity of angio-
genesis among HUVECs.
Laser doppler analysis of blood flow (Figure 3: upper panel)
Figure 3 (Upper Panel) showed that the ratios of ische-
mic/normal blood flow (INBF) did not differ among thefive groups, [i.e. sham control (SC) (group 1)], SC + Lc-
MPs (group 2), CLI only (group 3), CLI + Hs-MPs
(group 4), and CLI + Lc-MPs (group 5) on day 0 prior to
the CLI procedure. There was also no significant differ-
ence between groups 1 and 2, but it was significantly
and progressively reduced in groups 5 to 3 as compared
with groups 1 and 2 on day 2 after CLI induction. By
post-operative days 7 and 14, the ratio of INBF was sig-
nificantly reduced in group 3 compared to that in other
groups, significantly reduced in groups 4 and 5 than that
in groups 1 and 2, and notably reduced in group 4 than
that in group 5, but it did not differ between groups 1
and 2 (Figure 3). These findings imply that Lc-MP was
more effective than Hs-MP in restoring blood flow in
the ischemic limb.
Figure 3 Upper Panel) Ratio of ischemic/normal blood flow (INBF) by Laser Doppler scan on day 0 prior to procedure and on days 2, 7
and 14 after critical limb ischemia (CLI) procedure (n = 10). A) Showing normal blood flow at baseline, days 2, 7 and 14 of both hind limbs
among five groups. B) Analytical results of ratios of ischemic (left limb)/normal (right limb) blood flow (INBF) Laser Doppler at day 0 prior to CLI
procedure) and days 2, 7 and 14 after CLI procedure. By day 2, * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001; By day 7, * vs.
other groups with different symbols (*, †, ‡, §), p < 0.0001; By day 14, * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. Lower Panel)
Protein expressions of angiogenesis factors of ischemic quadriceps on day 14 following critical limb ischemia (CLI) procedure (n = 8). C) Protein
expression of vascular endothelial growth factor (VEGF); D) Protein expression of stromal cell-derived factor (SDF)-1α; E) Protein expression of
CXCR4; F) Protein expression of angiopoietin 1 (ANGPT 1); * vs. other groups with different symbols (*, †, ‡, §), p < 0.001. G) Protein expression of
hepatocyte growth factor (HGF); I) Protein expression of CD31; Protein expression of endothelial nitric oxide synthase (eNOS); * vs. other groups
with different symbols (*, †, ‡, §), p < 0.005. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test (n = 7). Symbols (*, †, ‡, §) indicate significance (at 0.05 level). SC = sham control; CLI = critical limb ischemia; Lc-MPs = lung-cancer
patient-derived microparticles; Hs-MPs = Healthy subject-derived microparticles.
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ischemic quadriceps by Day 14 after CLI procedure
(Figure 3: lower panel)
Figure 3 (Lower Panel) showed that the protein expres-
sions of VEGF (Figure 3-C), SDF-1α (Figure 3-D), CXCR4
(Figure 3-E), angiopoietin-1 (Figure 3-F) and HGF
(Figure 3-G) were lowest in groups 1 and 2 and highestin group 5, and significantly higher in group 4 than
those in group 3, but they were similar between groups
1 and 2. These findings suggest that expressions of
these angiogenesis markers, which only occur in condition
of ischemic stress, were significantly up-regulated in re-
sponse to Hs-MP and further notably reinforced after
Lc-MP treatment. Additionally, the protein expression
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ces of integrity of endothelial function and angiogenesis,
were lowest in group 3 and highest in groups 1 and 2,
and significantly higher in group 5 than in groups 4, but
they exhibited no difference between groups 1 and 2.
Immunofluorescent examination of Pro-angiogenic cells
in ischemic quadriceps by Day 14 after CLI procedure
(Figures 4, 5, and 6)
The results of IF staining showed that the numbers of
CD31+ (Figure 4-A to F) and vWF+ (Figure 4-G to L)
cells, two endothelial cell markers, were significantly
lower in group 3 than in other groups, significantly
lower in groups 4 and 5 than in groups 1 and 2, and sig-
nificantly lower in group 4 than in group 5, but they re-
vealed no difference between groups 1 and 2. Moreover,Figure 4 Immunofluorescence (IF) microscope (400×) findings of von
quadriceps by day 14 following CLI procedure (n = 8). A to E) Showing
groups with different symbols (*, †, ‡, §), p < 0.0001. G to K) Illustrating the
groups with different symbols (*, †, ‡, §), p < 0.0001. Scale bars in right low
one-way ANOVA, followed by Bonferroni multiple comparison post hoc tes
control; CLI = critical limb ischemia; Lc-MPs = lung-cancer patient-derived mthe numbers of SDF-1α+ (Figure 5 A to F), CXCR4+
(Figure 5 G to L), VEGF+ (Figure 6 A to F) and HGF+
(Figure 6-G to L) cells, four indicators of angiogenesis
biomarkers, were highest in group 5 and lowest in
groups 1 and 2, and significantly higher in group 4 than
in group 3, but they exhibited no difference between
groups 1 and 2. These findings imply that Lc-MP had
higher capacity than Hs-MP of promoting the retention
of pro-angiogenic cells in the ischemic limbs.
Quantitative analysis of IHC staining of ischemic
quadriceps and hematoxylin-eosin staining of lung tissue
on Day 14 after CLI procedure (Figure 7)
The results of IHC staining showed remarkably lower
number of small vessels (defined as < 15 μm) in group 3
than in other groups (Figure 7-A to F). It was also notablyWillebrand factor (vWF)+ and CD31+ stained cells in ischemic
the IF stain of CD31+ cells (white arrows) in five groups. F) * vs. other
IF stain of vWF+ cells (white arrows) in five groups. L) * vs. other
er corner represent 20 μm. All statistical analyses were performed by
t. Symbols (*, †, ‡, §) indicate significance (at 0.05 level). SC = sham
icroparticles; Hs-MPs = Healthy subject-derived microparticles.
Figure 5 Immunofluorescence (IF) microscope (400×) findings of stromal cell-derived factor (SDF)-1α+ and CXCR4+ stained cells in
ischemic quadriceps by day 14 following CLI procedure (n = 8). A to E) Showing the IF stain of SDF-1α+ cells (white arrows) in five groups.
F) * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. G to K) Illustrating the IF stain of CXCR4+ cells (white arrows) in five groups.
L) * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. Scale bars in right lower corner represent 20 μm. All statistical analyses were
performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §) indicate significance (at 0.05 level).
SC = sham control; CLI = critical limb ischemia; Lc-MPs = lung-cancer patient-derived microparticles; Hs-MPs = Healthy subject-derived microparticles.
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significantly lower in group 4 than that in group 5, but it
did not differ between groups 1 and 2. These findings
once more suggest that augmented angiogenesis/neovas-
cularization only develop in situation of ischemic stimula-
tion. Moreover, it was notably strengthened in the Lc-MPs
treatment group compared with animals after Hs-MPS
treatment in response to ischemic stress. Importantly, no
sign of tumorigenesis was noted in the ischemic limbs or
in lung tissue (Figure 7-G to I).
Protein expressions of fibrosis, anti-fibrosis, apoptosis,
and anti-apoptosis biomarkers in ischemic quadriceps by
Day 14 after CLI procedure (Figures 8 and 9)
The protein expressions of TGF-β (Figure 8-A) and
p-Smad3 (Figure 8-B), two fibrotic biomarkers, weresignificantly increased in CLI-Lc-MPs and further increased
in CLI than in SC and SC-Lc-MPs, but it displayed no
differences between later two groups. On the other
hand, the protein expressions of BMP-2 (Figure 8-C)
and p-Smad1/5 (Figure 8-D), two indices of anti-fibrosis,
showed an opposite pattern of fibrotic biomarkers among
the four groups. Additionally, the protein expression of
mitochondrial Bax (Figure 9-A), cytosolic Bax (Figure 9-B)
cleaved (i.e., active form) caspase 3 (Figure 9-C), and
cleaved PARP (Figure 9-D), and cytosolic Bax (a versed
pattern of mitochondrial Bax) (Figure 9-B), the indicators
of apoptosis, showed an identical pattern compared to
that of fibrosis, whereas the protein expressions of Bcl-
2 (Figure 9-E), an anti-apoptotic marker, showed a re-
versed pattern compared to that of fibrosis among the
four groups.
Figure 6 Immunofluorescence (IF) microscope (400×) findings of vascular endothelial growth factor (VEGF)+ and hepatocyte growth
factor (HGF)+ stained cells in ischemic quadriceps by day 14 following CLI procedure (n = 8). A to E) Showing the IF stain of VEGF+ cells
(white arrows) in five groups. F) * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. G to K) Illustrating the IF stain of HGF+ cells
(white arrows) in five groups. L) * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. Scale bars in right lower corner represent 20 μm.
All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §) indicate
significance (at 0.05 level). SC = sham control; CLI = critical limb ischemia; Lc-MPs = lung-cancer patient-derived microparticles; Hs-MPs = Healthy
subject-derived microparticles.
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This study, which investigated the impact of MPs on
promoting angiogenesis and restoration of blood flow in
ischemic limbs in a rodent model, yielded several strik-
ing implications. First, the results of HUVEC culturing
study proved that Lc-MP treatment enhanced angiogen-
esis, cell proliferation, and NO production as well as
VEGFR2 protein expressions, suggesting that MP
treatment augmented angiogenesis mainly through eli-
citing the VEGF signaling pathway. Second, both
ex vivo (i.e., aortic ring) and in vivo (i.e., ischemic
limb) studies demonstrated that MP therapy enhanced
angiogenesis. Third, the remarkably increased blood
flow to the ischemic limbs after MP treatment suggests
that MPs may also play a principal role in restoring themicrocirculation in other ischemia-induced organ in-
juries. Fourth, lung cancer-derived MPs were more ef-
fective than those derived from healthy subjects in
enhancing angiogenesis and restoring blood flow in the
ischemic regions. Importantly, our in vitro and in vivo
studies provided an outcome of scientifically mutual
authentication.
One important finding of the in vitro study using
aortic-ring and HUVEC cultures is the angiogenesis-
promoting capacity of Lc-MPs. In particular, Lc-MPs
were shown to augment HUVEC proliferation and NO
production (i.e., an indicator of angiogenesis). Our find-
ings are consistent with those of previous studies that
demonstrated MP-induced angiogenesis and differenti-
ation of bone marrow-derived endothelial progenitor
Figure 7 Immunohistochemical (IHC) (200×) staining of alpha-smooth muscle actin for quantification of small vessel (≤25.0 μm) in
ischemic quadriceps at day 14 after CLI induction (n = 8). A to E) Indicating IHC stain of number of small vessels (red arrows) in five groups.
F) * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. Scale bars in right lower corner represent 50 μm. G to I) Demonstrating the H.
E. staining for the lung parenchyma in SC + Lc-MPs (G), CLI + Hs-MPs (H), and CLI + Lc-MPs. No tumorigenesis was found in these three groups of
animals. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §)
indicate significance (at 0.05 level). SC = sham control; CLI = critical limb ischemia; Lc-MPs = lung-cancer patient-derived microparticles;
Hs-MPs = Healthy subject-derived microparticles.
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study is the in vitro demonstration of markedly up-
regulated VEGFR2 protein expressions in HUVECs after
Lc-MP treatment. In contrast, the protein expression of
bFGF (i.e., angiogenesis molecules) in HUVECs did not
show significant change in with and without Lc-PM
treatment. Intriguingly, one recent study has suggested
that MPs can act directly through the ligand/receptor
interaction or indirectly on angiogenesis by modulating
soluble factor production involved in endothelial cell dif-
ferentiation, proliferation, migration, and adhesion [30].
Previous studies have suggested that the PPAR alpha
and VEGF family of angiogenic factors and theirreceptors are essential for MP-induced differentiation
and angiogenesis [29,31]. Additionally, another previous
study has shown that circulating levels of PMs and cir-
culating endothelial cells correlated with prognosis, and
could be useful as prognostic markers in patients with
advanced non-small cell lung cancer [32]. In this way,
our finding is comparable to those of previous studies
[29-32], suggesting that VEGF receptor may be one of
the important signaling pathways in angiogenesis and
cell differentiation. Target therapy is one of the common
management strategies for advanced NSCLC. Recent
data has suggested that anti-VEGF monoclonal antibody
such as bevacizumab is an acceptable palliative drug for
Figure 8 Protein expressions of fibrotic and anti-fibrotic biomarkers in ischemic quadriceps on day 14 following critical limb ischemia
(CLI) procedure (n = 8). A) Protein expression of transforming growth factor (TGF)-β in four groups (SC = sham control; SC + Lc-MPs = sham
control + lung-cancer patient-derived microparticles; CLI = critical limb ischemia; CLI + Lc-MPs = critical limb ischemia + lung-cancer patient-derived
microparticles), * vs. other groups with different symbols (*, †, ‡), p < 0.001. B) Protein expression of phosphorylated (p)-Smad3 in four groups,
* vs. other groups with different symbols (*, †, ‡), p < 0.01. C) Protein expression of bone morphogenetic protein (BMP)-2 in four groups, * vs.
other groups with different symbols (*, †, ‡), p < 0.001. D) Protein expression of p-Smad1/5 in four groups, * vs. other groups with different
symbols (*, †, ‡), p < 0.01. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test.
Symbols (*, †, ‡) indicate significance (at 0.05 level).
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the support for potential clinical application of anti-
VEGF regimen in this setting.
The most important finding in the present study is
that, as compared to the SC group, administration of Lc-
MPs to SC animals did not result in any significant
change of blood flow in the ischemic limbs. On the
other hand, while Hs-MP therapy significantly increased
blood flow in the ischemic regions, Lc-MP further sig-
nificantly enhanced blood flow in the CLI area. The
finding, which was first identified by the present study,
highlights the superior potency of Lc-MP to that of
Hs-MP in enhancing angiogenesis which may help in
explaining tumor sprouting and augmented angiogenesis
for supporting tumor growth and metastasis. Ourfindings, therefore, support the finding of the previous
study that MPs plays an essential role on the propaga-
tion of non-small cell lung cancer [32].
An essential finding in the current study is that, as
compared to animals with ischemic limbs without treat-
ment, Hs-MP substantially enhanced and Lc-MP further
boosted the numbers of angiogenesis cells in the ische-
mic limbs. Another interesting finding in the present
study is that the number of small vessels showed an
identical pattern of changes compared to that of expres-
sion of the angiogenesis cells among these animals. Our
findings also reinforce those of previous studies demon-
strating enhancement of vasculogenesis after treatment
with platelet-derived or ischemic muscle-derived MPs in
experimental models of vascular injuries [33,34]. Another
Figure 9 Protein expressions of apoptotic and anti-apoptotic biomarkers in ischemic quadriceps on day 14 following critical limb
ischemia (CLI) procedure (n = 8). A) Protein expression of mitochondrial Bax (mito-Bax) in four groups (SC = sham control; SC + Lc-MPs = sham
control + lung-cancer patient-derived microparticles; CLI = critical limb ischemia; CLI + Lc-MPs = critical limb ischemia + lung-cancer patient-derived
microparticles), * vs. other groups with different symbols (*, †, ‡), p < 0.001. B) The protein expression of cytosolic Bax (cyto-Bax) in four groups,
* vs. other groups with different symbols (*, †, ‡), p < 0.001. C) Protein expression of cleaved caspase (c-Csp) 3 in four groups, * vs. other groups
with different symbols (*, †, ‡), p < 0.001. D) Protein expression of cleaved poly (ADP-ribose) polymerase (PARP), * vs. other groups with different
symbols (*, †, ‡), p < 0.001. E) The protein expression of Bcl-2, * vs. other groups with different symbols (*, †, ‡), p < 0.001.
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in the number of small vessels and pro-angiogenic cells
in the healthy limbs between control animals with and
without MP treatment. Again, these findings highlight
the therapeutic role of MPs only under the condition of
ischemia.
A principal finding in the present study is that the
protein expressions of pro-angiogenic factors were
markedly increased in CLI animals with MP treatment
as compared to those without. Besides, the expressions
of anti-apoptotic and anti-fibrotic biomarkers were re-
markably higher, whereas the apoptotic and fibrotic bio-
markers were notably lower in CLI animals with Lc-MP
treatment than in those without. Our previous studies
have also shown identical pattern of expressions of these
biomarkers in CLI animals without treatment [25,26].
Another interesting finding is that there was no alterna-
tion of these biomarkers between control animals with
and without MP treatment. Accordingly, our findings, in
addition to being consistent with the results of ourprevious studies [25,26], once more explain the restor-
ation of blood flow after MP treatment in a rodent
model of CLI.
Study limitations
This study has limitations. First, the potential long-term
side-effect of tumorigenesis from lung cancer-derived
MPs was not assessed in the current study. Second,
since the present in vitro study (Figure 2) did not screen
for all pro-angiogenic molecules/receptors acted on by
Lc-MPs other than VEGFR2 and bFGF, no such infor-
mation was available. Additionally, the findings from
Figure 2 did not allow drawing the conclusion that ef-
fects of MPs from healthy subjects were inferior to those
from cancer patients. Third, this study focused on the
investigation of angiogenesis rather than on the tumor
sprouting and metastasis. Fourth, we did not provide the
effects of MPs from healthy subjects in Figures 8 and 9.
Therefore, we did not know how specificity of the effects
of Lc-MPs on these biomarkers. Finally, although
Figure 10 Proposed mechanisms underlying the positive therapeutic effects of circulating microparticles on critical limb ischemia.
Lc-MPs = lung cancer-derived circulating microparticles; NO = nitric oxide; VEGFR2 = vascular endothelial growth factor receptor 2; SDF-1α = stromal
cell-derived factor 1 alpha; ANGPT = angiopoietin; eNOS = endothelial nitric oxide synthase; HGF = hepatocyte growth factor; vWF = von Willebrand
factor; IFBF = Ratio of ischemic to normal blood flow; PARP = poly (ADP-ribose) polymerase; TGF-β = transforming growth factor beta; BMP = bone
morphogenesis protein.
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study, the exact mechanisms underlying the therapeutic
effects of circulating MPs on improving the CLI are still
unclear. The proposed mechanisms by which MP treat-
ment salvaged CLI and improved the blood flow in ische-
mic area in a rodent CLI model have been summarized in
Figure 10.
In conclusion, our data not only provide evidence that
Lc-MP is more effective than Hs-MP in enhancing angio-
genesis, vascularization, and restoration of blood flow in
an animal model of CLI, but also suggest that Lc-MPs
may play a key role in the propagation of lung cancer.Additional file
Additional file 1: Determination of the effects of Lc-MPs on
Angiogenesis, Proliferation, Nitric Oxide (NO) Production, and
Expressions of Angiogenesis Factors. The procedures for determining
angiogenesis were based on our previous report [35]. In brief, HUVECs (104
cells) were incubated with MPs (3.0 x 105 or 6.0 x 105 particles); or vehicle for
72 hours. HUVECs were then plated on 96-well plates at 104 cells/well in
serum-free M199 culture medium mixed with cold Matrigel (Chemicon
international) for 5 hour incubation at 37°C in 5% CO2, respectively. Three
random images were taken for counting cluster, tube, and networkformations. To investigate the effect of Lc-MPs on NO production,
examination of NO production in HUVECs were performed by adding
5 µM 4-amino-5-methylamino-2’,7’-difluorofluorescein diacetate
(DAF-FM Diacetate; Molecular Probes) at 37°C for 30 minutes. Cells were
washed with PBS twice, and counterstained with Hoechst 33258 (0.5 µg/mL,
Sigma) for 30 minutes in room temperature. To determine the impact of
Lc-MPs on cellular proliferation, 5-bromodeoxyuridine (BrdU) (0.01 mM)
was used. Following 48 hours of BrdU incubation, in situ detection was
performed using the BrdU In-Situ Detection Kit (BD Biosciences Pharmingen,
USA). To determine the impact of MPs on the protein expressions of
VEGFR2 and basic-fibroblast growth factor (b-FGF), two indicators of
angiogenesis, HUVECs (5.0×105 cells) were cultured with low-dose
(1.0 x 104 particles) and high-dose (5.0 x 104 particles) MPs for time
courses of 6, 12 and 24 hrs (i.e., Cells were harvested after 6, 12, and
24hrs). Treatment of the HUVECs with the VEGF (50 ng/mL) served as a
positive control. The cells then were collected for Western blot
analysis.To assess the direct effect of Lc-MPs on angiogenesis in blood
vessel, aortic ring (from rat ascending aorta) was cultured with Lc-MPs
(i.e., ex vivo test) in M199 culture.
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